| Sign In to gain access to subscriptions and/or personal tools. |
Quality of life during the first 6 months of interferon-b treatment in patients with MSDepartment of Neurology, University Hospital `Vrije Universiteit', PO Box 7057, 1007 MB, Amsterdam, The Netherlands
Department of Neurology, University Hospital `Vrije Universiteit', PO Box 7057, 1007 MB, Amsterdam, The Netherlands
Department of Medical Psychology, `Vrije Universiteit', Amsterdam, The Netherlands
Department of Neurology, University Hospital `Vrije Universiteit', PO Box 7057, 1007 MB, Amsterdam, The Netherlands
Department of Neurology, University Hospital `Vrije Universiteit', PO Box 7057, 1007 MB, Amsterdam, The Netherlands
Department of Neurology, University Hospital `Vrije Universiteit', PO Box 7057, 1007 MB, Amsterdam, The Netherlands Objectives: To determine the quality of life (QoL) of MS patients during the initial 6 months of treatment with interferon-b (IFN-b). Furthermore, to determine whether changes in QoL relate to disability, emotional state, therapeutic expectations or side effect profile. Background: IFN-b has been shown to have beneficial effects on the course of MS. Since the aim of IFN-b treatment is not to cure but to slow down the disease it is important to know how this treatment affects QoL. Surprisingly, the impact of treatment with IFN-b on QoL measures has not been extensively studied so far. Methods: Case report documentation, including EDSS, SF-36 and MADRAS scores, of 51 relapsing-remitting MS patients treated with IFN-b was obtained at baseline and at months 1, 3 and 6. Patients also filled in a form about their expectations of therapy and a questionnaire on side effects. Results: During treatment there was a significant linear trend indicating improvement in the role-physical functioning (RPF) scale of the SF-36 (F1,50=4.9, P=0.032). A transient decrease at month 1 was found in the scale for bodily pain, indicating more experienced pain (F1,50=19.8, P50.001). Subgroup analysis showed that patients with most depressive symptoms on the MADRAS at baseline contributed most to the increase in RPF scores over time (F1,24=5,6 P=0.026). Furthermore, we found associations between adverse event scores and several domains of QoL. Conclusions: Our findings suggest that IFN-b therapy has an impact on QoL of MS patients in that it improves role-physical functioning and transiently worsens experienced bodily pain. QoL during treatment with IFN-b is influenced by depressive symptoms at baseline as well as by treatment-associated side-effects.
Key Words: multiple sclerosis • interferon-ß • quality of life
Multiple Sclerosis, Vol. 6, No. 5,
338-342 (2000) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
